Physician profile
Robert M Greenhagen
NPI 1649433848
$28,997.91
in general payments reported to CMS, 2019-2025
28 companies · $2,994 in 2025
The $2,994 reported for 2025 was more than what 89% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,601 · 2020: $1,274 · 2021: $4,782 · 2022: $4,286 · 2023: $7,147 · 2024: $4,913 · 2025: $2,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,793 · Travel and Lodging: $6,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,792.53 |
| Travel and Lodging | $6,261.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $23,626.89 | 2019-2025 | Ortholoc 2 Lapifuse, Viaflow, Inbone |
| Smith+Nephew, INC. | $3,930.44 | 2019-2025 | Grafix Pl, Collagenase Santyl, Stravix |
| Abbott Laboratories | $172.94 | 2021 | |
| Osiris Therapeutics INC. | $135.29 | 2019 | |
| Grt US Holding, INC. | $87.87 | 2021-2022 | |
| Horizon Therapeutics Plc | $86.87 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $86.61 | 2021-2024 | Nuzyra |
| Kerecis Limited | $82.57 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Organogenesis INC. | $79.91 | 2021-2025 | Apligraf |
| Medtronic, INC. | $74.81 | 2021 | |
| Averitas Pharma INC. | $65.75 | 2023-2024 | Qutenza |
| Pylant Medical | $61.87 | 2022 | |
| Orpyx Medical Technologies US INC. | $53.38 | 2023 | Orpyx Si |
| Treace Medical Concepts, INC. | $52.85 | 2022-2024 | |
| Nevro Corp. | $50.33 | 2022-2023 | Senza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $43.37 | 2020 | |
| Innovation Technologies INC | $42.80 | 2022-2024 | Irrisept |
| Integra Lifesciences Corporation | $37.25 | 2022 | |
| Kci USA, INC. | $33.80 | 2019-2020 | |
| Becton, Dickinson and Company | $32.28 | 2025 | Surgiphor |
| Rsw Medical Company, INC. | $31.32 | 2019 | |
| Advanced Oxygen Therapy INC. | $28.68 | 2021 | |
| Orthofix Medical, INC. | $22.65 | 2025 | Accelstim |
| Baudax Bio INC. | $19.42 | 2021 | |
| Conetic Solutions, INC. | $16.09 | 2021 | |
| Heron Therapeutics, INC. | $15.06 | 2023 | Zynrelef |
| Zimmer Biomet Holdings, INC. | $13.63 | 2022 | |
| Bsn Medical INC | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Greenhagen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.